BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gupta G, Yakubu I, Bhati CS, Zhang Y, Kang L, Patterson JA, Andrews-Joseph A, Alam A, Ferreira-Gonzalez A, Kumar D, Moinuddin IK, Kamal L, King AL, Levy M, Sharma A, Cotterell A, Reichman TW, Khan A, Kimball P, Stiltner R, Baldecchi M, Brigle N, Gehr T, Sterling RK. Ultra-short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipients. Am J Transplant 2020;20:739-51. [PMID: 31652392 DOI: 10.1111/ajt.15664] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 16.7] [Reference Citation Analysis]
Number Citing Articles
1 Alghamdi W, Lotfy K, Weernink C, Alsolami E, Jevnikar A, Luke P, Skaro A, Qumosani K, Brahmania M, Marotta P, Hosseini-moghaddam SM, Teriaky A. Hepatitis C positive organ transplantation to negative recipients at a multiorgan Canadian transplant centre: ready for prime time. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02107-1] [Reference Citation Analysis]
2 Concepcion BP, Binari LA, Schaefer H, Rega S, Feurer I, Shawar S, Naik R, Hickman L, Walker J, Kapp M, Birdwell KA, Langone A, Helderman JH, Ann Sarrell B, Kochar G, Dubray B, Smith K, O'Dell H, DeMers A, Shelton P, Perri R, Shaffer D, Forbes RC. Kidney Transplantation From Hepatitis C Viremic Deceased Donors to Aviremic Recipients in a Real-world Setting. Transplant Direct 2021;7:e761. [PMID: 34514116 DOI: 10.1097/TXD.0000000000001217] [Reference Citation Analysis]
3 Prakash K, Aslam S. New updates in the world of hepatitis C virus infected organ transplantation. Curr Opin Organ Transplant 2020;25:364-70. [PMID: 32520787 DOI: 10.1097/MOT.0000000000000785] [Reference Citation Analysis]
4 Feld JJ, Cypel M, Kumar D, Dahari H, Pinto Ribeiro RV, Marks N, Kamkar N, Bahinskaya I, Onofrio FQ, Zahoor MA, Cerrochi O, Tinckam K, Kim SJ, Schiff J, Reichman TW, McDonald M, Alba C, Waddell TK, Sapisochin G, Selzner M, Keshavjee S, Janssen HLA, Hansen BE, Singer LG, Humar A. Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study. Lancet Gastroenterol Hepatol. 2020;5:649-657. [PMID: 32389183 DOI: 10.1016/s2468-1253(20)30081-9] [Cited by in Crossref: 42] [Cited by in F6Publishing: 25] [Article Influence: 21.0] [Reference Citation Analysis]
5 Gupta G, Yakubu I, Zhang Y, Kimball P, Kang L, Mitchell K, Ijioma S, Carroll N, Patterson J, Shinbashi M, Kumar D, Moinuddin I, Kamal L, King A, Bhati C, Levy M, Cotterell A, Khan A, Sharma A, Sterling R. Outcomes of short-duration antiviral prophylaxis for hepatitis C positive donor kidney transplants. Am J Transplant 2021. [PMID: 34212479 DOI: 10.1111/ajt.16747] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
6 Chang SH, Merzkani M, Lentine KL, Wang M, Axelrod DA, Anwar S, Schnitzler MA, Wellen J, Chapman WC, Alhamad T. Trends in Discard of Kidneys from Hepatitis C Viremic Donors in the United States. Clin J Am Soc Nephrol 2021;16:251-61. [PMID: 33451990 DOI: 10.2215/CJN.10960720] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
7 Stewart ZA, Shah SA, Rolls JA, Guarrera JV, Kandaswamy R, Axelrod DA. Best practice recommendations for the use of hepatitis C viremic donor organs for hepatitis C virus naïve recipients. Clin Transplant 2021;:e14381. [PMID: 34086371 DOI: 10.1111/ctr.14381] [Reference Citation Analysis]
8 Terrault NA, Burton J, Ghobrial M, Verna E, Bayer J, Klein C, Victor D, Mohan S, Trotter J, Dodge J, Niemann CU, Rubin RA. Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCV-Viremic Donors. Hepatology 2021;73:2110-23. [PMID: 32926749 DOI: 10.1002/hep.31551] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
9 Bethea E, Arvind A, Gustafson J, Andersson K, Pratt D, Bhan I, Thiim M, Corey K, Bloom P, Markmann J, Yeh H, Elias N, Kimura S, Dageforde LA, Cuenca A, Kawai T, Safa K, Williams W, Gilligan H, Sise M, Fishman J, Kotton C, Kim A, Rogers CC, Shao S, Cote M, Irwin L, Myoung P, Chung RT. Immediate administration of antiviral therapy after transplantation of hepatitis C-infected livers into uninfected recipients: Implications for therapeutic planning. Am J Transplant. 2020;20:1619-1628. [PMID: 31887236 DOI: 10.1111/ajt.15768] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
10 Daloul R, Pesavento T, Goldberg DS, Reese PP. A review of kidney transplantation from HCV-viremic donors into HCV-negative recipients. Kidney Int 2021:S0085-2538(21)00669-4. [PMID: 34237327 DOI: 10.1016/j.kint.2021.06.034] [Reference Citation Analysis]
11 Kuntzen C, Bagha Z. The Use of Hepatitis C Virus–Positive Organs in Hepatitis C Virus–Negative Recipients. Clinics in Liver Disease 2022. [DOI: 10.1016/j.cld.2022.01.012] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Sise ME, Goldberg DS, Kort JJ, Schaubel DE, Alloway RR, Durand CM, Fontana RJ, Brown RS Jr, Friedewald JJ, Prenner S, Landis JR, Fernando M, Phillips CC, Woodle ES, Rike-Shields A, Sherman KE, Elias N, Williams WW, Gustafson JL, Desai NM, Barnaba B, Norman SP, Doshi M, Sultan ST, Aull MJ, Levitsky J, Belshe DS, Chung RT, Reese PP. Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection. J Am Soc Nephrol 2020;31:2678-87. [PMID: 32843477 DOI: 10.1681/ASN.2020050686] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 6.5] [Reference Citation Analysis]
13 Kothadia JP, Bhalla A, Molnar MZ, Mohan R, Balaraman V, Talwar M, Helmick R, Eymard C, Clark I, Jain R, Faust TW, Vanatta JM, Eason JD, Nair SP. Liver Outcome in Renal Transplant Recipients Who Acquired Hepatitis C Infection From an Infected Graft: Study Based on Liver Biopsy Findings. Transplantation Direct 2022;8:e1342. [DOI: 10.1097/txd.0000000000001342] [Reference Citation Analysis]
14 Humar SS, Pinzon N, Cypel M, Abbey S. Lung transplant recipient attitudes and beliefs on accepting an organ that is positive for hepatitis C virus. Transpl Infect Dis 2021;:e13684. [PMID: 34228382 DOI: 10.1111/tid.13684] [Reference Citation Analysis]
15 Durand CM, Barnaba B, Yu S, Brown DM, Chattergoon MA, Bair N, Naqvi FF, Sulkowski M, Segev DL, Desai NM. Four-Week Direct-Acting Antiviral Prophylaxis for Kidney Transplantation From Hepatitis C-Viremic Donors to Hepatitis C-Negative Recipients: An Open-Label Nonrandomized Study. Ann Intern Med 2021;174:137-8. [PMID: 32894697 DOI: 10.7326/M20-1468] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
16 Azhar A, Tsujita M, Talwar M, Balaraman V, Bhalla A, Eason JD, Nouer SS, Sumida K, Remport A, Hall IE, Griffin R, Rofaiel G, Molnar MZ. CMV specific T cell immune response in hepatitis C negative kidney transplant recipients receiving transplant from hepatitis C viremic donors and hepatitis C aviremic donors. Ren Fail 2022;44:831-41. [PMID: 35546431 DOI: 10.1080/0886022X.2022.2072744] [Reference Citation Analysis]
17 Feld JJ, Ward JW. Key Elements on the Pathway to HCV Elimination: Lessons Learned From the AASLD HCV Special Interest Group 2020. Hepatol Commun 2021;5:911-22. [PMID: 34141979 DOI: 10.1002/hep4.1731] [Reference Citation Analysis]
18 Torabi J, Rocca JP, Ajaimy M, Melvin J, Campbell A, Akalin E, Liriano LE, Azzi Y, Pynadath C, Greenstein SM, Le M, Goldstein DY, Fox AS, Carrero J, Weiss JM, Powell T, Racine AD, Reinus JF, Kinkhabwala MM, Graham JA. Commercial insurance delays direct-acting antiviral treatment for hepatitis C kidney transplantation into uninfected recipients. Transpl Infect Dis. 2021;23:e13449. [PMID: 32810315 DOI: 10.1111/tid.13449] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Cohen-Bucay A, Francis JM, Gordon CE. Progress in hepatitis C virus management in chronic kidney disease. Curr Opin Nephrol Hypertens 2021;30:493-500. [PMID: 34054074 DOI: 10.1097/MNH.0000000000000729] [Reference Citation Analysis]
20 Franco A, Moreso F, Sancho A, Esforzado N, Paul J, Llorente S, Crespo M, Guirado L, Melilli E, Roncero FG. Protocol for Optimizing the Use of Kidneys From Donors With Seropositivity for Hepatitis C Virus in Seronegative Recipients. Transplant Proc 2021;53:2655-8. [PMID: 34657711 DOI: 10.1016/j.transproceed.2021.09.013] [Reference Citation Analysis]
21 Yazawa M, Balaraman V, Tsujita M, Azhar A, Talwar M, Bhalla A, Potukuchi PK, Eason JD, Kovesdy CP, Molnar MZ. Donor hepatitis C antibody positivity misclassifies kidney donor profile index in non-hepatitis C-infected donors: time to revise the kidney donor profile index - a retrospective cohort study. Transpl Int 2020;33:1732-44. [PMID: 32935416 DOI: 10.1111/tri.13743] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Logan C, Yumul I, Cepeda J, Pretorius V, Adler E, Aslam S, Martin NK. Cost-effectiveness of using hepatitis C viremic hearts for transplantation into HCV-negative recipients. Am J Transplant 2021;21:657-68. [PMID: 32777173 DOI: 10.1111/ajt.16245] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
23 El Helou G, Jay C, Nunez M. Hepatitis C virus and kidney transplantation: Recent trends and paradigm shifts. Transplantation Reviews 2022;36:100677. [DOI: 10.1016/j.trre.2021.100677] [Reference Citation Analysis]
24 Raasikh T, Jamali T, Flores A, Cotton RT, Ramanathan V, Tan HP, Hernaez R. Systematic review: hepatitis C viraemic allografts to hepatitis C-negative recipients in solid organ transplantation. Aliment Pharmacol Ther 2021;54:571-82. [PMID: 34265111 DOI: 10.1111/apt.16508] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
25 Bohorquez H, Bugeaud E, Bzowej N, Scheuermann J, Hand J, Bruce D, Carmody I, Cohen A, Joshi S, Seal J, Sonnier D, Therapondos G, Girgrah N, Anders S, Loss GE. Liver Transplantation Using Hepatitis C Virus-Viremic Donors Into Hepatitis C Virus-Aviremic Recipients as Standard of Care. Liver Transpl. 2020;. [PMID: 33098277 DOI: 10.1002/lt.25925] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
26 Weinfurtner K, Reddy KR. Hepatitis C viraemic organs in solid organ transplantation. J Hepatol. 2021;74:716-733. [PMID: 33212088 DOI: 10.1016/j.jhep.2020.11.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Azhar A, Binari LA, Joglekar K, Tsujita M, Talwar M, Balaraman V, Bhalla A, Eason JD, Hall IE, Rofaiel G, Forbes RC, Shaffer D, Concepcion BP, Molnar MZ. Association between ezetimibe usage and hepatitis C RNA levels in uninfected kidney transplant recipients who received hepatitis C infected kidneys. Clin Transplant 2021;:e14485. [PMID: 34523744 DOI: 10.1111/ctr.14485] [Reference Citation Analysis]
28 Hudson MR, Webb AR, Logan AT, Silverman A, Brueckner AJ. Outcomes of hepatitis C virus nucleic acid testing positive donors in aviremic recipients with delayed direct-acting antiviral initiation. Clin Transplant 2021;:e14386. [PMID: 34132438 DOI: 10.1111/ctr.14386] [Reference Citation Analysis]
29 Lushniak SA, Durand CM. Donors with human immunodeficiency virus and hepatitis C virus for solid organ transplantation: what's new. Curr Opin Infect Dis 2022;35:321-9. [PMID: 35849522 DOI: 10.1097/QCO.0000000000000840] [Reference Citation Analysis]
30 Doherty DT, Athwal V, Moinuddin Z, Augustine T, Prince M, van Dellen D, Khambalia HA. Kidney Transplantation From Hepatitis-C Viraemic Donors:Considerations for Practice in the United Kingdom. Transpl Int 2022;35:10277. [DOI: 10.3389/ti.2022.10277] [Reference Citation Analysis]
31 Aslam S, Grossi P, Schlendorf KH, Holm AM, Woolley AE, Blumberg E, Mehra MR; working group members. Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus statement. J Heart Lung Transplant 2020;39:418-32. [PMID: 32362393 DOI: 10.1016/j.healun.2020.03.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
32 Liu CH, Kao JH. Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5. Hepatol Int 2022. [PMID: 35876967 DOI: 10.1007/s12072-022-10390-z] [Reference Citation Analysis]
33 Czarnecka P, Czarnecka K, Tronina O, Baczkowska T, Durlik M. Utilization of HCV viremic donors in kidney transplantation: a chance or a threat? Ren Fail 2022;44:434-49. [PMID: 35260039 DOI: 10.1080/0886022X.2022.2047069] [Reference Citation Analysis]
34 Edmonds C, Carver A, DeClercq J, Choi L, Peter M, Schlendorf K, Perri R, Forbes RC, Concepcion BP. Access to hepatitis C direct-acting antiviral therapy in hepatitis C-positive donor to hepatitis C-negative recipient solid-organ transplantation in a real-world setting. Am J Surg 2021:S0002-9610(21)00528-6. [PMID: 34548142 DOI: 10.1016/j.amjsurg.2021.09.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Zhang H, Liu Q, Hu S, Zhong M, Peng F, Guo Y, Fang C, Nie M, Tan L, Dai H, Xie X, Peng L, Lan G, Petrakis I. Utilization of HCV Viremic Kidneys with Genotyping/Subtyping-Free Sofosbuvir/Velpatasvir Treatment Strategy: Experience from China. BioMed Research International 2022;2022:1-8. [DOI: 10.1155/2022/3758744] [Reference Citation Analysis]
36 Lentine KL, Peipert JD, Alhamad T, Caliskan Y, Concepcion BP, Forbes R, Schnitzler M, Chang SH, Cooper M, Bloom RD, Mannon RB, Axelrod DA. Survey of Clinician Opinions on Kidney Transplantation from Hepatitis C Virus Positive Donors: Identifying and Overcoming Barriers. Kidney360 2020;1:1291-9. [PMID: 33251523 DOI: 10.34067/KID.0004592020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
37 Molnar MZ, Potluri VS, Schaubel DE, Sise ME, Concepcion BP, Forbes RC, Blumberg E, Bloom RD, Shaffer D, Chung RT, Strohbehn IA, Elias N, Azhar A, Shah M, Sawinski D, Binari LA, Talwar M, Balaraman V, Bhalla A, Eason JD, Besharatian B, Trofe-Clark J, Goldberg DS, Reese PP. Association of donor hepatitis C virus infection status and risk of BK polyomavirus viremia after kidney transplantation. Am J Transplant 2021. [PMID: 34613666 DOI: 10.1111/ajt.16834] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
38 Molnar MZ, Azhar A, Tsujita M, Talwar M, Balaraman V, Bhalla A, Podila PSB, Kothadia J, Agbim UA, Maliakkal B, Satapathy SK, Kovesdy CP, Nair S, Eason JD. Transplantation of Kidneys From Hepatitis C Virus-Infected Donors to Hepatitis C Virus-Negative Recipients: One-Year Kidney Allograft Outcomes. Am J Kidney Dis 2021;77:739-747.e1. [PMID: 33333148 DOI: 10.1053/j.ajkd.2020.10.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
39 Friebus-Kardash J, Gäckler A, Kribben A, Witzke O, Wedemeyer H, Treckmann J, Herzer K, Eisenberger U. Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients. Transpl Infect Dis 2019;21:e13146. [PMID: 31306562 DOI: 10.1111/tid.13146] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
40 Axelrod DA, Lentine KL, Balakrishnan R, Chang SH, Alhamad T, Xiao H, Kasiske BL, Bloom RD, Schnitzler MA. Financial Evaluation of Kidney Transplant With Hepatitis C Viremic Donors to Uninfected Recipients. Transplant Direct 2020;6:e627. [PMID: 33204825 DOI: 10.1097/TXD.0000000000001056] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Chevallier E, Büchler M, Caillard S, Bouvier N, Colosio C, Rivalan J, Sayegh J, Bertrand D, Le Meur Y, Thierry A, Garrouste C, Rerolle JP, Rostaing L, Gatault P. Chronic Hepatitis C Virus Infection After Kidney Transplantation With or Without Direct-Acting Antivirals in a Real-Life Setting: A French Multicenter Experience. Transplant Proc 2020;52:3179-85. [PMID: 32636068 DOI: 10.1016/j.transproceed.2020.06.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Fabrizi F, Cerutti R, Alfieri CM, Messa P. Updated View on Kidney Transplant from HCV-Infected Donors and DAAs. Pharmaceutics 2021;13:496. [PMID: 33917382 DOI: 10.3390/pharmaceutics13040496] [Reference Citation Analysis]
43 Duerr M, Liefeldt L, Friedersdorff F, Choi M, Öllinger R, Hofmann J, Budde K, Schrezenmeier E, Halleck F. Pan-Genotype Pre-Exposure Prophylaxis (PrEP) Allows Transplantation of HCV-Positive Donor Kidneys to Negative Transplant Recipients. J Clin Med 2020;10:E89. [PMID: 33383877 DOI: 10.3390/jcm10010089] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Pawlotsky J, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. EASL recommendations on treatment of hepatitis C: Final update of the series☆. Journal of Hepatology 2020;73:1170-218. [DOI: 10.1016/j.jhep.2020.08.018] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 56.5] [Reference Citation Analysis]
45 Sawinski D, Wong T, Goral S. Current state of kidney transplantation in patients with HIV, hepatitis C, and hepatitis B infection. Clin Transplant 2020;34:e14048. [PMID: 32700341 DOI: 10.1111/ctr.14048] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Nguyen T, Sise ME, Delgado C, Williams W, Reese P, Goldberg D. Race, Education, and Gender Disparities in Transplantation of Kidneys From Hepatitis C Viremic Donors. Transplantation 2021;105:1850-7. [PMID: 33141804 DOI: 10.1097/TP.0000000000003511] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
47 Kappus MR, Wolfe CR, Muir AJ. Direct-Acting Antivirals and Organ Transplantation: Is There Anything We Can't Do? J Infect Dis. 2020;222:S794-S801. [PMID: 33245347 DOI: 10.1093/infdis/jiaa420] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
48 Stewart ZA, Stern J, Ali NM, Kalia HS, Khalil K, Jonchhe S, Weldon EP, Dieter RA, Lewis TC, Funches N, Crosby S, Seow M, Berger JC, Dagher NN, Gelb BE, Watkins AC, Moazami N, Smith DE, Kon ZN, Chang SH, Reyentovich A, Angel LF, Montgomery RA, Lonze BE. Clinical and Financial Implications of 2 Treatment Strategies for Donor-derived Hepatitis C Infections. Transplant Direct 2021;7:e762. [PMID: 34514117 DOI: 10.1097/TXD.0000000000001222] [Reference Citation Analysis]
49 Feng Z, Zhang J, Tan W, Wang C, Chen Q, Shen C, Fan H, Zhang Y, Huang P, Yue M. Efficacy and Safety of Direct-Acting Antivirals in Kidney Transplantation From HCV-Viremic Donors to Negative Recipients: A Meta-Analysis. Front Med (Lausanne) 2022;9:802686. [PMID: 35665327 DOI: 10.3389/fmed.2022.802686] [Reference Citation Analysis]